MedPath

Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia

Phase 3
Completed
Conditions
Presbyopia
Interventions
Registration Number
NCT03804268
Lead Sponsor
Allergan
Brief Summary

A study to evaluate the efficacy, safety, and pharmacokinetics of pilocarpine hydrochloride (HCl) ophthalmic solution (AGN-190584) when administered bilaterally, once daily for 30 days in participants with presbyopia.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
323
Inclusion Criteria
  • Subjective complaints of poor near vision that impact activities of daily living
Exclusion Criteria
  • History of cataract surgery, phakic intraocular lens surgery, corneal inlay surgery, radial keratotomy, or any intraocular surgery
  • Use of any topical ophthalmic medications, including artificial tears other than the study medications during the study
  • Use of temporary or permanent punctal plugs or history of punctal cautery in one or both eyes
  • Corneal abnormalities (including keratoconus, corneal scar, Fuchs' endothelial dystrophy, guttata, or edema) in either eye that are likely to interfere with visual acuity
  • Narrow iridocorneal angles (Shaffer grade ≤2 or lower on gonioscopy examination), history of angle-closure glaucoma, or previous iridotomy
  • Diagnosis of any type of glaucoma or ocular hypertension

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
VehicleVehicleParticipants received one drop of vehicle in each eye, once daily, for up to 30 days.
Pilocarpine HCl Ophthalmic SolutionPilocarpine HCl Ophthalmic SolutionParticipants received one drop of pilocarpine HCl ophthalmic solution 1.25% in each eye, once daily, for up to 30 days.
Primary Outcome Measures
NameTimeMethod
Percentage of Participants Gaining 3 Lines or More in Mesopic, High-contrast, Binocular Distance-Corrected Near Visual Acuity (DCNVA) at Day 30, Hour 3Baseline (Day 1) to Day 30 (Hour 3)

Visual acuity for near (40 centimeters (cm)) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 candelas per square meter (cd/m\^2) measured at the target. Percentage of participants with 3 lines or more improvement from Baseline in mesopic, high-contrast DCNVA are reported.

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants Gaining 3-lines or More in Mesopic, High-contrast, Binocular, DCNVA at Day 30, Hour 10Baseline (Day1) to Day 30 (Hour 10)

Visual acuity for near (40cm) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 cd/m\^2measured at the target. Percentage of participants with 3 lines or more improvement from Baseline in mesopic, high-contrast, binocular DCNVA are reported.

Percentage of Participants Achieving 20/40 or Better in Photopic, High-contrast, Binocular, DCNVA at Day 30, Hour 1Day 30 (Hour 1)

Visual acuity for near (40 cm) target was measured in photopic conditions using an eye chart. Photopic condition was defined as high lighting ≥80 cd/m\^2 measured at the target. Percentage of participants achieving 20/40 or better in photopic, high-contrast, binocular, DCNVA are reported.

Mean Change From Baseline in Mesopic Near Vision Presbyopia Task-based Questionnaire (NVPTQ) Performance Score at Day 30, Hour 3Baseline (Day 1) to Day 30 (Hour 3)

NVPTQ had 12 questions on 4 reading tasks(reading a paragraph from book, excerpts from an article in newspaper, portion of a nutrition label, and a section from restaurant menu). Participants completed specific reading tasks under mesopic conditions without any near-vision correction and answered 3 questions for each task, rating their vision-related reading ability as 0=I could not read any text due to problems seeing up close,1=poor,2=fair,3=good,4=very good,5=excellent;impact of squinting on performance as 0=No,I did not squint, 1=Yes,squinting helped me read some/all text, 2=Yes,but I still could not read any of the text; and satisfaction as 0=very dissatisfied to 4=very satisfied. The score based on vision related ability and impact of squinting=(Book testlet+Newspaper testlet+Menu testlet+Nutrition Label testlet)/(testlets with non-missing responses), total possible score of 0-5. Higher scores=better outcomes;positive change from Baseline=improved performance(reading ability).

Percentage of Participants Gaining 3 Lines or More in Mesopic, High-contrast, Binocular Distance-Corrected Near Visual Acuity (DCNVA) at Day 30, Hour 6Baseline (Day 1) to Day 30 (Hour 6)

Visual acuity for near (40 cm) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 candelas per square meter measured at the target. Percentage of participants with 3 lines or more improvement from Baseline in mesopic, high-contrast DCNVA are reported.

Percentage of Participants Gaining 3-lines or More in Mesopic, High-contrast, Binocular, DCNVA at Day 30, Hour 8Baseline (Day 1) to Day 30 (Hour 8)

Visual acuity for near (40 cm) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 candelas per square meter measured at the target. Percentage of participants with 3 lines or more improvement from Baseline in mesopic, high-contrast DCNVA are reported.

Change From Baseline in Mesopic, High-contrast, Binocular DCNVA Letters at Day 30, Hour 0.5Baseline (Day 1) to Day 30 (Hour 0.5)

Visual acuity for near (40 cm) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 cd/m\^2 measured at the target. A positive change from Baseline indicates improvement in visual acuity. Mixed effect model for repeated measures (MMRM) was used for analyses.

Change From Baseline in Photopic, High-contrast, Binocular Distance-corrected Intermediate Visual Acuity (DCIVA) Letters at Day 30, Hour 3Baseline (Day 1) to Day 30 (Hour 3)

Visual acuity for intermediate (66 cm) target was measured in photopic conditions using an eye chart. Photopic condition was defined as high lighting ≥80 cd/m\^2 measured at the target. A positive change from Baseline indicates improvement in visual acuity. MMRM was used for analyses.

Mean Change From Baseline in Presbyopia Impact and Coping Questionnaire (PICQ) Coping Score at Day 30, Hour 3Baseline (Day 1) to Day 30 (Hour 3)

PICQ=20 questions about impact experienced by participants due to their problems over past 7 days.PICQ Coping domain had 8 items: 1:Normal-sized text,2:Small-sized text,3:Information on a computer,4:Information on a cell phone,5:Increase font size,6:Use glasses to read close,12:Hold reading materials farther out/closer,13:Squint to read. Each item had response categories:0=never to 4=all the time. Items 3, 4, 5, and 6 had additional response categories with values of 9/10 to indicate the question is not applicable to participant and were assigned missing values.PICQ Coping Score:(Item 1,2 Testlet+Item 3,4 Testlet+Item 5+Item 6+Item 12+Item 13)/non-missing responses to the 6 components of coping score where Items 1,2 Testlet=(Item1+Item2)/non-missing responses to Items 1,2;Items 3,4 Testlet=(Item3+Item4)/non-missing responses to Items 3, 4. Score ranges:0=to least amount of coping to 4=greatest amount of coping. Higher scores=poorer outcome; a negative change from Baseline=improvement.

Change From Baseline in Mesopic, High-contrast, Binocular DCNVA Letters at Day 30, Hour 0.25Baseline (Day 1) to Day 30 (Hour 0.25)

Visual acuity for near (40 cm) target was measured in mesopic conditions. Mesopic condition was defined as low lighting 3.2 to 3.5 cd/m\^2 measured at the target. A positive change from Baseline indicates improvement in visual acuity. MMRM was used for analyses.

Percentage of Participants Achieving 20/40 or Better in Photopic, High-contrast, Binocular, DCNVA at Day 30, Hour 3Day 30 (Hour 3)

Visual acuity for near (40 cm) target was measured in mesopic conditions using an eye chart. Photopic condition was defined as high lighting ≥80 cd/m\^2 measured at the target. Percentage of participants achieving 20/40 or better in photopic, high-contrast, binocular, DCNVA are reported.

Mean Change From Baseline in PICQ Impact Score at Day 30, Hour 3Baseline (Day 1) to Day 30 (Hour 3)

PICQ had 20 questions about impact experienced by participants due to their problems seeing up over past 7 days. PICQ Impact domain had 6 items: Item 9:Rely on others,15:rest eyes,16:Feel older,17:Feel self-conscious,19:Take longer to complete a task,20:Inconvenient. First 5 impacts items included response categories: 0=never to 4=all the time. Item 20 had response categories: 0=not at all to 4=extremely. Item 9 included an additional response category with a value of 9 to indicate question was not applicable to participant and the responses were assigned missing values. PICQ Impacts Score=\[(Item9+Item15+Items16,17Testlet+Item19+Item20)/(nonmissing responses to 5 components of impacts score)\] where Items 16,17 Testlet=(Item16+Item17)/non-missing responses to Items 16 and 17. PICQ Impact score ranges from 0 to 4; with 0=least amount of impacts to 4=greatest amount of impacts. Higher scores correspond to poorer outcomes. A negative change from Baseline=improvement.

Mean Change From Baseline in Mesopic NVPTQ Satisfaction Score at Day 30, Hour 3Baseline (Day 1) to Day 30 (Hour 3)

NVPTQ had 12 questions on 4 reading tasks(reading a paragraph from book, excerpts from an article in newspaper, portion of a nutrition label, and a section from restaurant menu). Participants completed specific reading tasks under mesopic conditions without any near-vision correction and answered 3 questions for each task, rating their vision-related reading ability as 0=I could not read any text due to problems seeing up close to 5=excellent; impact of squinting on performance as 0=No, I did not squint, 1=Yes, squinting helped me read some/all text, 2=Yes, but I still could not read any of the text; and satisfaction as 0=very dissatisfied,1=dissatisfied,2=neither satisfied nor dissatisfied,3=satisfied, 4=very satisfied. The score based on satisfaction items=(Book testlet+Newspaper testlet+Menu testlet+Nutrition Label testlet)/(testlets with non-missing responses) for a total possible score of 0 to 4. Higher scores=better outcomes; a positive change from Baseline=higher satisfaction.

Trial Locations

Locations (36)

American Institute of Research

🇺🇸

Los Angeles, California, United States

Eye Research Foundation

🇺🇸

Newport Beach, California, United States

Danbury Eye Physicians and Surgeons P.C.

🇺🇸

Danbury, Connecticut, United States

Bruce Segal, MD

🇺🇸

Delray Beach, Florida, United States

Research Centers of America

🇺🇸

Hollywood, Florida, United States

Price Vision Group

🇺🇸

Indianapolis, Indiana, United States

The Ohio State University

🇺🇸

Columbus, Ohio, United States

Florida Eye Associates

🇺🇸

Melbourne, Florida, United States

Key-Whitman Eye Center

🇺🇸

Dallas, Texas, United States

R and R Eye Research, LLC

🇺🇸

San Antonio, Texas, United States

Haas Vision Center

🇺🇸

Colorado Springs, Colorado, United States

Assil Eye Institute

🇺🇸

Beverly Hills, California, United States

Arizona Eye Center

🇺🇸

Chandler, Arizona, United States

Sabates Eye Centers

🇺🇸

Leawood, Kansas, United States

Schwartz Laser Eye Center

🇺🇸

Scottsdale, Arizona, United States

The Eye Associates

🇺🇸

Bradenton, Florida, United States

Seidenberg Protzko Eye Associates

🇺🇸

Havre De Grace, Maryland, United States

Direct Helpers Research Center

🇺🇸

Hialeah, Florida, United States

Scott & Christie and Associates, PC

🇺🇸

Cranberry Township, Pennsylvania, United States

Hoopes, Durrie, Rivera Research

🇺🇸

Draper, Utah, United States

Martel Eye Medical Group

🇺🇸

Rancho Cordova, California, United States

Alterman, Modi & Wolter

🇺🇸

Poughkeepsie, New York, United States

Rochester Ophthalmological Group, PC

🇺🇸

Rochester, New York, United States

Mundorf Eye Center

🇺🇸

Charlotte, North Carolina, United States

EyeCare Professionals DWA Insight Research Clinic, LLC

🇺🇸

Powell, Ohio, United States

PNV Clinical Research LLC

🇺🇸

San Antonio, Texas, United States

Southern College of Optometry

🇺🇸

Memphis, Tennessee, United States

Hill Country Eye Center

🇺🇸

Cedar Park, Texas, United States

Black Hills Regional Eye Institute

🇺🇸

Rapid City, South Dakota, United States

Vance Thompson Vision

🇺🇸

Sioux Falls, South Dakota, United States

Grutzmacher & Lewis, A Medical Corporation DBA Sacramento Eye Consultants

🇺🇸

Sacramento, California, United States

USF Eye Institute

🇺🇸

Tampa, Florida, United States

The Eye Care Institute

🇺🇸

Louisville, Kentucky, United States

Tauber Eye Center

🇺🇸

Kansas City, Missouri, United States

Devers Eye Institute

🇺🇸

Portland, Oregon, United States

Nashville Vision Associates

🇺🇸

Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath